Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 30 systematic reviews/meta-analyses. ^[1-30]
• Faricimab: Comparable efficacy in visual acuity as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) scale and retinal thickness to other anti-Vascular Endothelial Growth Factor (VEGF) agents for Retinal Vein Occlusion (RVO) (aflibercept, abicipar, bevacizumab, brolucizumab, pegaptanib, or ranibizumab), with a higher percentage of patients free from retinal fluid compared to aflibercept (every 8 weeks), ranibizumab, and bevacizumab. It also significantly reduces the number of annual injections. Comparable safety profile to other anti-VEGF agents; reduced risk of serious ocular adverse events compared to brolucizumab.
• Brolucizumab: Demonstrates superior effectiveness in improving Best Corrected Visual Acuity (BCVA) compared to aflibercept and ranibizumab, with a lower presence of intraretinal fluid (IRF) or subretinal fluid (SRF) (weighted mean difference [WMD], -8.2 letter score; 95% Confidence Interval (CI), -11.79 to -4.50; P < .001; Grading of Recommendations Assessment, Development, and Evaluation (GRADE) [2334 eyes], low; 7 studies; 2114 eyes). For SRF related to RVO, WMD was 3.1 letter score (95% CI, 0.05 to 6.18; P = .05; GRADE, low certainty of evidence; 6 studies; 1931 eyes). No significant difference in retinal thickness compared to control. Higher incidence of serious ocular adverse events compared to aflibercept and ranibizumab.
• Aflibercept for RVO: Comparable efficacy to ranibizumab in Central Retinal Vein Occlusion (CRVO), but with greater improvement in BCVA and Central Retinal Thickness (CRT) in real-world studies. No statistically significant difference in Branch Retinal Vein Occlusion (BRVO). No significant differences in ocular or non-ocular adverse events compared to other treatments.
• Aflibercept for Diabetic Macular Edema (DME): Slightly more effective in visual acuity improvement and CRT reduction compared to ranibizumab and bevacizumab, with fewer injections required. No significant differences in ocular or non-ocular adverse events compared to other treatments.
• There is no population type or subgroup information available in the reviewed studies.